Kimberly A. Singletary, PhD and Marshall H. Chin, MD, MPH
The Roadmap to Advance Health Equity offers specific, actionable antiracist payment reform strategies to help ensure that everyone can receive good health services and optimize their health.
AMA J Ethics. 2023;25(1):E55-65. doi:
10.1001/amajethics.2023.55.
Despite a tendency to react otherwise, there is no obvious reason to believe that economically disadvantaged people ought not to be exposed to the same levels of research risk as the rest of the population.
A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.
Cynthia E. Schairer, PhD, Caryn Kseniya Rubanovich, MS, and Cinnamon S. Bloss, PhD
Questions about data privacy need to be addressed when research institutions negotiate with companies developing mobile health applications. Commercial terms of use and data sharing notifications should be reviewed before use in human subject research settings.
AMA J Ethics. 2018;20(9):E864-872. doi:
10.1001/amajethics.2018.864.
The all-payer rate setting model of pricing combines a uniform payment method with a single rate that all private and public insurers pay for a specific service, thus improving price transparency for patients.
AMA J Ethics. 2015;17(8):770-775. doi:
10.1001/journalofethics.2015.17.8.pfor1-1508.
Decisions about where and to whose professional stewardship patients are admitted are influenced by federal policies of which physicians might not be aware.
AMA J Ethics. 2023;25(12):E901-908. doi:
10.1001/amajethics.2023.901.
Research in the PED and PICU is essential to medical understanding of the efficacy of emergency interventions. Researchers must minimize the additional stress that consent and participation in research entail for pediatric patients and their families.
Eitan Neidich, Alon B. Neidich, David A. Axelrod, MD, and John P. Roberts, MD
Geographic disparities in availability of organs for transplant have spawned for-profit companies that help patients get on waitlists in more than one region and arrange travel for them if an organ becomes available.